D. Medical Gains Most in Week on U.S. Diabetes Guide Listing

D. Medical Industries Ltd. (DMED) surged the most in more than a week after the maker of drug delivery devices said its infusion set has been listed in a U.S. diabetes consumer guide.

The shares (DMED) rose 3.1 percent, the biggest intraday gain since Dec. 25, to 5.30 shekels at 12:32 p.m. in Tel Aviv, giving the Tirat Carmel, Israel-based company a market value of 43.3 million shekels ($11 million).

D. Medical said its Spring Universal Infusion Set for the monitoring of insulin delivery has been listed in the American Diabetes Association 2012 Consumer Guide, according to a filing with the Tel Aviv Stock Exchange today.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.